Use of the Site of Subcutaneous Insulin Administration for the Measurement of Glucose in Patients With Type 1 Diabetes by Lindpointner, Stefan et al.
Use of the Site of Subcutaneous Insulin
Administration for the Measurement of
Glucose in Patients With Type 1 Diabetes
STEFAN LINDPOINTNER, MD
1
STEFAN KORSATKO, MD
1
GERD K¨ OHLER, MD
1
HANS K¨ OHLER, MSC
2
ROLAND SCHALLER, MSC
2
RUTHY KAIDAR, MSC
3
OFER YODFAT, MD
3
LUKAS SCHAUPP, PHD
1,2
MARTIN ELLMERER, PHD
1
THOMAS R. PIEBER, MD
1,2
WERNER REGITTNIG, PHD
1
OBJECTIVE — To simplify and improve the treatment of patients with type 1 diabetes, we
ascertained whether the site of subcutaneous insulin infusion can be used for the measurement
of glucose.
RESEARCH DESIGN AND METHODS — Three special indwelling catheters (24-
gauge microperfusion [MP] catheters) were inserted into the subcutaneous adipose tissue of
subjects with type 1 diabetes (n  10; all C-peptide negative). One MP catheter was perfused
with short-acting insulin (100 units/ml, Aspart) and used for insulin delivery and simultaneous
glucose sampling during an overnight fast and after ingestion of a standard glucose load (75 g).
As controls, the further two MP catheters were perfused with an insulin-free solution (5%
mannitol) and used for glucose sampling only. Plasma glucose was measured frequently at the
bedside.
RESULTS — Insulin delivery with the MP catheter was adequate to achieve and maintain
normoglycemiaduringfastingandafterglucoseingestion.Tissueglucoseconcentrationsderived
with the insulin-perfused catheter agreed well with plasma glucose levels. Median correlation
coefﬁcient and median absolute relative difference values were found to be 0.93 (interquartile
range 0.91–0.97) and 10.9%, respectively. Error grid analysis indicated that the percentage
number of tissue values falling in the clinically acceptable range is 99.6%. Comparable analysis
results were obtained for the two mannitol-perfused catheters.
CONCLUSIONS — Ourdatasuggestthatestimationofplasmaglucoseconcentrationsfrom
the glucose levels directly observed at the site of subcutaneous insulin infusion is feasible and its
quality is comparable to that of estimating plasma glucose concentrations from glucose levels
measured in insulin-unexposed subcutaneous tissue.
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T
ype1diabetesispresentlytreatedby
self-administration of insulin, either
by a subcutaneous bolus injection
using a hypodermic needle (e.g., syringe,
insulin pen) or by a continuous subcuta-
neous infusion using an indwelling cath-
eter connected to an insulin pump (1,2).
Type 1 diabetic patients furthermore sep-
arately self-monitor glucose levels in
blood obtained by ﬁnger-pricking to
guide the adjustment of insulin dosage,
food consumption, and physical activity
(1,2). To simplify and improve the glu-
cose management in diabetes, we sought
to determine whether the site of subcuta-
neous insulin administration can also be
usedforthemeasurementofglucose.Asa
ﬁrststep,werecentlyassessedthekinetics
of insulin action on the tissue glucose
concentration at the insulin delivery site
in the presence of euglycemic blood
plasma levels (3). Using the euglycemic
clamp technique together with special in-
dwellingcatheters(microperfusionormi-
crodialysis catheters) for coupling insulin
delivery with glucose sampling at the
same tissue site, we found that within 60
min after exposing adipose tissue of
healthy humans to a standard 100
units/ml insulin preparation, insulin’s ef-
fect on the tissue glucose concentration
saturates and a stable ratio between the
tissue and plasma glucose concentration
isattained.Thisattainmentofsteady-state
insulin action conditions at the delivery
site indicates that glucose sensing and in-
sulin delivery may be carried out simulta-
neously at the same adipose tissue site via
asingletissuecatheter.Tofurthervalidate
this single-port treatment approach, the
objective of the present study was to as-
certainintype1diabeticpatientswhether
tissue glucose concentrations observed at
the site of subcutaneous insulin delivery
can be used to estimate plasma glucose
levels. To accomplish this, microperfu-
sion (MP) catheters were inserted in adi-
pose tissue of type 1 diabetic subjects and
used to carry out glucose sampling and
simultaneous insulin delivery during an
overnight fast and after ingestion of a
standard glucose load (oral glucose toler-
ance test [OGTT]).
RESEARCH DESIGN AND
METHODS— Ten subjects with type
1 diabetes (two females and eight males;
age 39.8  2.9 years, range 27–57; BMI
25.3  1.0 kg/m
2, range 21.1–29.5,
means  SE) participated in this study.
Their mean duration of diabetes was
22.9  2.6 years (range 7–35) and their
percent A1C averaged 7.6  0.3% (range
5.7–8.6%, normal range 4.3–5.9%). Pa-
tients were all without residual endoge-
nous insulin secretion, as indicated by
undetectable C-peptide levels in blood
plasma (i.e., 22 pmol/l). Three patients
were treated with continuous subcutane-
ous insulin infusion and seven with mul-
tiple daily injections of insulin. At the
time of the study, patients had no evi-
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cations and, apart from insulin, were not
taking any medication known to inﬂuence
carbohydrate metabolism and subcutane-
ous insulin absorption. Written informed
consent was obtained after the purpose,
nature,andpotentialrisksofthestudywere
explained to the subjects. The studies were
approved by the ethics committee of the
Medical University of Graz.
Study design
Thediabeticsubjectswereadmittedtothe
clinical research center at 2230. Sub-
jectstreatedwithmultipledailyinjections
hadbeeninstructedtoleaveouttheinjec-
tion of long-acting insulin on the evening
of the study. On admission to the clinical
research center, subjects with continuous
subcutaneous insulin infusion treatment
were asked to disconnect their own insu-
lin pump. At 2300, an intravenous
catheter was inserted into an arm vein for
blood withdrawal during the night. After
catheter insertion, three 24-gauge MP
catheters (4,5) were placed into the peri-
umbilical subcutaneous adipose tissue.
The distance between adjacent catheters
was 35 mm. Subsequently, peristaltic
pumps (Minipuls 3; Gilson, Villiers-le-
Bel, France) were attached to the inﬂow
and outﬂow tubing of each catheter (Fig.
1). One catheter was then perfused with a
rapid-acting insulin solution (100 units/
ml, Aspart; Novo Nordisk, Bagsvaerd,
Denmark) to allow insulin delivery and
simultaneoussamplingofinterstitialﬂuid
(ISF)duringtheexperiment.Thetwofur-
ther catheters were perfused with an in-
sulin-free solution (5% mannitol) and
used for ISF sampling only. After starting
catheter perfusion, an equilibration pe-
riod of 60 min elapsed before the catheter
efﬂuentsampleswerecollectedin60-min
fractions in vials kept on ice. Outﬂow
rates of all catheters were maintained at a
constant value (0.45 l/min) through-
out the experiment. The insulin delivery
rate of the insulin-perfused catheter was
adjusted by simply adjusting the inﬂow
rate of the catheter (dual pump operation
mode,Fig.1A).Adjustmentsintheinﬂow
rate were done on the basis of frequent
plasma glucose measurements (every
10–30 min) to slowly achieve and main-
tain normoglycemia (6 mmol/l) over-
night. For comparison purposes, the
inﬂow rates applied in one mannitol-
perfusedcatheter(Fig.1B)weresimilarto
the periodically adjusted inﬂow rates of
the insulin-perfused catheter (Fig. 1A),
whereastheinﬂowrateappliedinthesec-
ond mannitol-perfused catheter was
identical to its outﬂow rate (Fig. 1C). On
thenextday,at0700,ahandorforearm
vein was cannulated to allow blood with-
drawal during the subsequent OGTT
phase of the experiment. The forearm
with this catheter was then placed in a
thermoregulated box to arterialize the ve-
nous blood. At 0900, the subject ingested
75 g glucose dissolved in 300 ml of water
(Glucoral; Unipack, Wr.-Neustadt, Aus-
tria). Twenty minutes before glucose
ingestion, an insulin bolus was adminis-
tered over a period of 15 min via the in-
sulin-perfused MP catheter. Bolus
administration periods of comparable
length are used in some commercially
available insulin pump models (6). The
amountofinsulinadministeredasabolus
was determined by using medical records
on the subject’s insulin sensitivity factor
(i.e., subject’s insulin-to-carbohydrate ra-
tio). After administration of the insulin
bolus, the basal insulin delivery via the
insulin-perfused MP catheter was contin-
ued and periodically adjusted so as to re-
establish normal plasma glucose by 5h
after glucose ingestion. During the 8-h
OGTT phase and during the 2-h period
preceding initiation of the OGTT, the
catheter efﬂuent samples were collected
in 30-min fractions, and plasma glucose
concentrations were determined every
5–30 min. If during experiments the
Figure 1—Schematic of the experimental setup for assessing the feasibility of estimating plasma
glucoseconcentrationsfromtheISFglucoselevelsobservedattheinsulindeliverysite.A–C:Three
MP catheters were inserted into subcutaneous adipose tissue of diabetic subjects (n  10). One
catheter (MPI) was used for glucose sampling and simultaneous insulin delivery (A), and, as
controls, two catheters (MPM1 and MPM2) were used for glucose sampling only (B and C). The
catheter for glucose sampling and insulin delivery was perfused with a rapid-acting insulin solu-
tion(100units/ml,Aspart)usingtwoperistalticpumps(A),withoneattachedtotheinﬂowtubing
and one to the outﬂow tubing (dual-pump operation mode). Insulin delivery rate was adjusted by
adjustingthedifferencebetweentheinﬂowandoutﬂowrateofthecatheter.Theoutﬂowconveying
the extracted tissue glucose was collected in vials. The efﬁciency by which glucose was extracted
via diffusion from the ISF of the tissue into the catheter (glucose recovery) was measured by
applying the ionic reference technique (4,5). The catheters used for glucose sampling only (MPM1
and MPM2) were perfused with an insulin-free solution (5% mannitol) using either a single-pump
operationmodewheretheinﬂowequaledtheoutﬂowrate(C)oradual-pumpoperationmode(B)
where the inﬂow and outﬂow rates equaled those applied in the insulin-perfused MP catheter (A).
Glucose sampling from the insulin infusion site
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3.22mmol/l(58mg/dl),thesubjectswere
asked to ingest additional glucose.
Microperfusion and analytical
procedures
MP catheters applied were of concentric
design with a cylindrical inner and outer
tube (4,5). The outer tube consisted of a
conventional intravenous 24-G cannula
(shaft length: 19 mm, Neoﬂon; Becton
Dickinson, Helsingborg, Sweden) in
which 27 perforations (each 0.3 mm in
diameter) were formed in the cannula
wall using an Excimer Laser (LZH, Han-
nover, Germany). Two 750-mm lengths
of Tygon tubing (inner diameter: 0.19
mm; Cole-Parmer, Vernon Hills, IL) were
used to connect catheter inlet and outlet
with perfusate reservoir and sampling
vial, respectively.
Plasma glucose concentrations were
measured at the bedside using a Beckman
Glucose Analyzer II (Beckman Instru-
ments,Fullerton,CA)withacoefﬁcientof
variation (CV) of 2%. The glucose con-
centrations in catheter efﬂuents were de-
termined using an automated CMA600
analyzer (CMA/Microdialysis, Solna,
Sweden)withawithin-runCVof2%.The
conductivities in the plasma, perfusate,
and catheter efﬂuent samples were mea-
suredusingacontactlessconductivityde-
tector (TraceDec; I.S.T., Strasshof,
Austria). The electrical conductivity was
determined with a within-run CV of
1%. The plasma C-peptide concentra-
tions were determined using a two-site
enzyme immunoassay (C-peptide ELISA;
Mercodia,Uppsala,Sweden)withalower
limit of quantiﬁcation of 22 pmol/l. A1C
was measured by high-performance liq-
uidchromatography(HA-8160;Menarini
Diagnostics, Florence, Italy).
Data analysis
The ISF glucose concentration was calcu-
lated (4,5) as the glucose concentration
in the catheter efﬂuent sample divided by
the glucose recovery of the catheter (R).
Therecovery(orexchangeefﬁciency)was
determined for each sampling period as
R  (Cout  Cin)/(Cpl  Cin), where Cin,
Cout, and Cpl are the measured electrical
conductivity in the perfusate, the efﬂuent
sample, and the corresponding plasma
sample, respectively. This method (ionic
referencetechnique[4,5])allowedpoten-
tial recovery changes caused by changes
in the catheter characteristics (e.g.,
changes in perfusate inﬂow rates) and/or
undesired local variations in the tissue
microenvironment (e.g., blood ﬂow
changes, accumulation of edematous ﬂu-
ids) to be detected. Application of this
technique was possible, because the elec-
trical conductivity in the used catheter
perfusates was either negligible (manni-
tol) or low compared with that in blood
plasma (Aspart: 22.2% of average Cpl).
Because each efﬂuent sample was col-
lected over a speciﬁed time interval (i.e.,
60-min and 30-min intervals), the con-
centration in an efﬂuent sample was re-
garded as an average concentration over
the collection period. Thus, the derived
ISF glucose values were considered valid
at the midpoint of the interval, and an
observed change in the ISF glucose con-
centration was considered as a time-
averaged reﬂection of the changes that
occurred in the plasma concentration
during a collection interval. Estimates of
plasma glucose concentration (termed
“tissue glucose concentrations”) were de-
rived from the ISF glucose levels by using
a prospective one-point calibration pro-
cedure (7) that consisted of dividing the
ISFglucosevalueswiththeISF-to-plasma
glucose ratio calculated from the ISF glu-
cose concentration and corresponding
mean plasma glucose concentration ob-
served during the 60-min sampling pe-
riod at the beginning of each experiment.
Agreement between the tissue glucose
concentrations and directly measured
plasma glucose concentrations was as-
sessed by applying error grid analysis and
the method of residuals (8,9). Agreement
index data obtained from the application
of the method of residuals and the error
grid analysis were examined with Fried-
man’s test and Fisher’s exact test,
respectively.Implicitintheone-pointcal-
ibration method is the assumption that
there is a proportional relationship (Y 
B  X) between the plasma glucose (X)
and ISF glucose concentrations (Y). This
assumptionwastestedbyperformingcor-
relation and linear regression analysis of
the full plasma and ISF glucose dataset.
Correlation analysis was performed using
Pearson’s product-moment correlation
coefﬁcient, and linear regression analysis
was performed by the least squares
method. To detect potential effects of fast
changes in plasma glucose and insulin
concentrations on the relationship be-
tween plasma glucose levels and catheter-
derivedISFglucoseconcentrations,linear
regressionanalyseswereadditionallyper-
formed on a fasting dataset containing
plasma and ISF glucose values observed
during the overnight (euglycemic) phase
of the experiment (8 to 0 h), and on an
OGTT dataset containing plasma and ISF
glucose values observed during the hy-
perglycemic/hyperinsulinemic phase of
thestudy(0–8h).Coefﬁcientandparam-
eter data obtained from correlation and
linear regression analysis were examined
with Friedman’s test or Wilcoxon’s
signed-rank test. A P value 0.05 was
considered to indicate statistical signiﬁ-
cance. Normality of data were assessed
using normal probability plots. Homoge-
nity of variances in the linear regression
datawereassessedusingplotsofresiduals
againstﬁttedvalues.Dataarepresentedas
means  SE or as median and quartile
values.Dataanalysiswasperformedusing
MATLAB (MathWorks, Natick, MA) and
SPSS (SPSS, Chicago, IL) software
packages.
RESULTS
Plasma and ISF glucose time courses
Insulin delivery with the MP catheter was
successful both in achieving and main-
taining a stable normal plasma glucose
during the overnight fasting as well as in
reestablishing near-normal plasma glu-
cose by 4–5 h after the ingestion of glu-
cose (Fig. 2A–C and supplementary
Fig.1,availableinanonlineappendixat
http://care.diabetesjournals.org/cgi/
content/full/dc09-1532/DC1). In addi-
tion, glucose concentration time courses
observed in the ISF sampled with the three
MP catheters paralleled those seen in
plasma (supplementary Fig. 1). The basal
insulin delivery rates used during the
overnight and OGTT period averaged
1.04  0.11 and 0.85  0.16 units/h,
respectively. The amount of insulin given
as a bolus averaged 7.8  0.8 units
(Fig. 2A).
Relationship between plasma and
ISF glucose concentrations
Results from the correlation analysis of
ISF glucose values against plasma glucose
values are given in the supplementary Ta-
ble 2. The correlation coefﬁcient for the
insulin-perfused catheters (MPI)w a s
found to be high (median: 0.93; inter-
quartile range: 0.91–0.97) and did not
differ from that obtained for the manni-
tol-perfusedcatheters(versusMPM1:0.94
[0.88–0.97] and MPM2: 0.95 [0.91–
0.98]; P  0.67 with Friedman’s test). In
addition, regression analysis of plasma
glucose against ISF glucose values
showedthattheinterceptvaluesobtained
for insulin-perfused catheters (MPI:
Lindpointner and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 597Figure 2—Comparison of plasma and ISF-derived glucose concentrations observed during an overnight fast and OGTT in diabetic subjects. A:
Average time course (n  10, means  SE) of plasma glucose concentration (F) and the tissue glucose concentration obtained with the MP catheter
used for insulin delivery and simultaneous glucose sampling (MPI,  ). A also shows the average time course (n  10, means  SE) of the insulin
deliveryrate(bars)usedtocontrolglucoseconcentrationduringexperiments.BandC:Averagetimecourse(n10,meansSE)ofplasmaglucose
(F) and the tissue glucose obtained with the mannitol-perfused MP catheters (MPM1 and MPM2,  ). D: Error grid analysis results for the
insulin-perfused MP catheter (MPI): One of 268 data points (0.4%) fell outside of the clinically acceptable region A and B. E: Error grid analysis
resultsforthemannitol-perfusedcatheterMPM1:Twoof266datapoints(0.8%)wereoutsideoftheclinicallyacceptableregionAandB.F:Errorgrid
analysis results for the mannitol-perfused catheter MPM2: Three of 248 data points (1.2%) fell outside of the clinically acceptable region A and B. In
A, the tendency toward lower tissue glucose concentrations than plasma glucose levels at the end of the OGTT is mainly caused by subject 8, whose
tissue glucose concentration time course of the insulin-perfused catheter was an apparent outlier, with very low values during the last4ho ft h e
experiment (supplementary Fig. 1).
Glucose sampling from the insulin infusion site
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and mannitol-perfused catheters (MPM1:
0.31 mmol/l [0.27 to 1.19 mmol/l];
MPM2: 0.03 mmol/l [0.36 to 0.18
mmol/l]) are not different from zero (P 
0.19 with Wilcoxon’s signed-rank test).
Results from an additional regression
analysis performed with the straight-line
forced through the origin of regression
graphs (i.e., intercept was assumed to be
zero)aregiveninsupplementaryTables3
and4.Thestandarderrorsoftheslopesas
well as the root mean square errors ob-
tained from this regression were similar
for the insulin-perfused and mannitol-
perfused catheters (P  0.49 with Fried-
man’s test). These regression results,
together with the results from the corre-
lation analysis, indicate that there is a
strong proportional relationship between
plasma glucose levels and catheter-
derived ISF glucose values. Furthermore,
theslopeoftheregressionlinederivedfor
the insulin-perfused catheters (MPI:
0.726 [0.712–0.774]) was by 16%
lower than the slopes obtained for the
mannitol-perfused catheters (P  0.002
with Friedman’s test). There was no dif-
ference between the slopes obtained for
the two mannitol-perfused catheters
(MPM1: 0.862 [0.801–0.916] vs. MPM2:
0.859[0.833–0.977];P0.16withWil-
coxon’s signed-rank test). Results from
additional regression analyses performed
on the fasting and OGTT datasets are
given in supplementary Tables 5 and 6.
Comparison of the analysis results
showed that slopes and standard errors of
the slopes obtained for insulin-perfused
andmannitol-perfusedcathetersfromthe
OGTT dataset are similar to those ob-
tainedforinsulin-perfusedandmannitol-
perfused catheters from the fasting
dataset (MPI: P  0.48, MPM1: P  0.41,
and MPM2: P  0.08, all with Wilcoxon’s
signed-rank test).
Comparison between plasma and
tissue glucose concentrations
Tissue glucose time courses that were de-
rived from the ISF glucose time courses
using the prospective one-point calibra-
tion procedure are shown in supplemen-
tary Fig. 1 and Fig. 2A–C. Error grid
analysis indicated (Fig. 2D–F)t h a tt h e
percentage number of the tissue values
that fall in the clinically acceptable range
(zones A and B) is high for the insulin-
perfused catheters (99.6%) and compara-
ble to that obtained for the mannitol-
perfused catheters (versus 99.2% for
MPM1 and 98.8% for MPM2, P  0.87
withFisher’sexacttest).Furthermore,ap-
plying the method of residuals, the resid-
ual means and 2 SD values obtained for
the insulin-perfused catheters were 5.6%
(6.0 to 12.4%) and 31.6% (26.4 to
34.6%), respectively. These values were
similar to those calculated for the manni-
tol-perfused catheters (P  0.49 with
Friedman’s test; supplementary Table 1).
In addition, the median absolute relative
difference calculated for the insulin-
perfused catheters (10.9%) was compara-
ble to that of mannitol-perfused catheters
(versus 10.5 and 10.1% for MPM1 and
MPM2, respectively). Overall, the statisti-
cal analysis suggests that the quality of
estimation of plasma glucose concentra-
tions from the ISF glucose levels directly
observed at the adipose tissue site of in-
sulin delivery is comparable to that of es-
timating plasma glucose concentrations
from the ISF glucose levels measured in
insulin-unexposed tissue.
CONCLUSIONS— The present in-
vestigation demonstrates that estimation
of plasma glucose concentrations from
the glucose levels directly observed at the
site of subcutaneous insulin infusion is
feasible in type 1 diabetic patients. Thus,
glucose sensing and insulin delivery may
be combined at the same adipose tissue
site using a single catheter. Such a single-
porttreatmentapproachmayofferseveral
important advantages over present-time
insulin replacement approaches (1) and
recently proposed dual-port treatment
strategies (10,11). First, it permits a sig-
niﬁcant reduction in the number of treat-
ment-related needle-sticks, because the
subcutaneously inserted catheter serves
the double purpose of delivering insulin
and sensing glucose and because the ﬁn-
gerstick testing of blood glucose is only
needed to calibrate the ISF-based glucose
sensing. Second, it allows a reduction in
the size of the treatment system, because
both the sensing and delivery compo-
nents can be fully integrated into one de-
sign, and certain device components
implemented in dual-port systems can be
reduced in number (e.g., power supply
units) or can even be eliminated (e.g., re-
ceiver-transmitter modules). Third, it in-
creases patient convenience and possibly
allows higher treatment compliance,
leading to an improved glucose manage-
ment. Finally, the single-port treatment
approach may provide the basis for the
future development of an autonomous
device able to self-regulate insulin deliv-
ery (artiﬁcial pancreas).
Estimates of the plasma glucose con-
centration were derived from the ob-
served ISF glucose concentrations by
applying a prospective one-point calibra-
tionprocedure(7)thatimplicitlyassumes
that there is a proportional relationship
between plasma and ISF glucose concen-
trations. This assumption of proportion-
ality may be well satisﬁed because
correlation and linear regression analysis
of plasma glucose concentrations and ISF
glucose levels from insulin-exposed and
insulin-unexposed tissue sites indicated
that the derived intercepts are not differ-
ent from zero and that glucose concentra-
tions in the ISF correlated closely with
those in plasma (supplementary Table 2).
Furthermore, correlation coefﬁcients,
standarderrorsoftheslopes,aswellasthe
root mean square errors obtained from
correlation and linear regression analysis
of the full ISF and plasma glucose data-
sets (supplementary Tables 2–4) were
similar for insulin-exposed and insulin-
unexposed tissue sites. In addition, re-
gression analyses performed individually
on fasting and OGTT datasets showed
that slopes and standard errors of the
slopes obtained for insulin-exposed and
insulin-unexposed tissue sites during the
fasting were similar to those obtained for
insulin-exposed and insulin-unexposed
tissue sites during the OGTT, thereby in-
dicating that changes in plasma insulin
and glucose concentrations did not affect
the relationship between plasma glucose
concentrations and ISF glucose levels at
these tissue sites (supplementary Tables
5 and 6). Overall, these results suggest
that exposure of adipose tissue to stan-
dard insulin preparations did not alter
the strength of the proportional rela-
tionship between plasma glucose con-
centrations and ISF glucose levels of
adipose tissue.
Agreement between the ISF-based esti-
mates of plasma glucose levels and directly
measured plasma glucose concentrations
wasassessedbyapplyingerrorgridanalysis
and the method of residuals (8,9). In the
present study, values of the agreement in-
dexesobtainedfortheISF-basedestimation
of plasma glucose concentration from insu-
lin-unexposed tissue sites (Fig. 2D–F and
supplementary Table 1) were similar to or
better than those previously obtained
with commercial continuous glucose-
sensing devices that also use the ISF of
(insulin-unexposed) adipose tissue for
the measurement of glucose (12–15).
Furthermore, values of the agreement
indexes derived in the present study for
Lindpointner and Associates
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similar to those derived for the insulin-
unexposed adipose tissue (Fig. 2D–F,
supplementary Table 1). Thus, our data
indicate that the quality of estimation of
plasma glucose concentrations from the
ISF glucose levels directly observed at
the adipose tissue site of insulin deliv-
ery is comparable to that of estimating
plasma glucose concentrations from the
ISF glucose levels measured in insulin-
unexposed tissue.
Recently,weassessedthekineticsofin-
sulin action on the ISF glucose concentra-
tion at the site of subcutaneous insulin
delivery (3). In this earlier study, after the
startofinsulindelivery,weobservedanini-
tial delay of 60 min before insulin’s effect
on the ISF glucose concentration at the de-
livery site saturated, and the ISF-to-plasma
glucoseconcentrationratioattainedsteady-
statevalues.Thesevalueswere20%lower
than the ISF-to-plasma glucose ratio values
observed during the baseline period before
the start of insulin delivery. In the current
study,wedeterminedISFglucoselevelsun-
der steady-state insulin action conditions.
To achieve this, the ISF sampling from the
insulin delivery site was begun 60 min after
the start of insulin delivery. Thus, compar-
ison of the slopes derived for the insulin-
exposed and insulin-unexposed tissue
(supplementary Table 2) allowed for esti-
mation of the magnitude of the steady-state
effect of insulin on the ISF glucose concen-
trationattheinsulindeliverysiteindiabetic
patients. We found that the slopes derived
fortheinsulin-exposedtissuewereonaver-
age16%lowerthantheslopesderivedfor
the insulin-unexposed tissue (supplemen-
taryTable2),therebyconﬁrmingourrecent
ﬁndingsonthemagnitudeofinsulin’seffect
on the ISF glucose concentration in human
adipose tissue (3).
Besides the effect of insulin on the fat
cell glucose uptake, an additional mecha-
nism potentially inﬂuencing the glucose
concentration at the site of insulin delivery
may be the local dilution of the ISF by the
insulin solvent. To separate and quantitate
these potential effects on the glucose con-
centrationattheinsulindeliverysite,oneof
the two mannitol catheters (MPM1) was op-
erated using also the dual-pump technique
withpumpspeedsidenticaltothoseusedin
the operation of the insulin catheter (Fig.
1B). We reasoned that if an increase in the
perfusateﬂowfractiondirectedtothetissue
(due to an increase in the difference be-
tween the speeds of inﬂow and outﬂow
pumps) is causing a dilution of the ISF sur-
rounding the catheter, then there will be a
decreaseintheefﬁciencyofexchangeofsol-
utes between the ISF and the perfusates of
the two catheters operated with the dual-
pump technique (MPI and MPM1). We
found that increases in the basal delivery
rates did not dilute the ISF at the insulin
delivery site. In contrast, bolus administra-
tions apparently diluted the ISF at the insu-
lin delivery site as both exchange efﬁciency
(recovery) and efﬂuent glucose concentra-
tionweredecreasedduringandshortlyafter
the bolus administration period (i.e., be-
tween 30 and 0 min; supplementary Fig.
2). However, when accounting for this re-
covery change in the calculation of the tis-
sue glucose concentration from the efﬂuent
glucose concentration (by using the ionic
reference technique), the obtained tissue
glucoseconcentrationsagreedwellwiththe
corresponding plasma glucose levels also
during bolus administration periods (Fig.
1AandB),therebyindicatingthatbolusad-
ministrations did not disturb steady-state
insulin action conditions at the insulin de-
livery site. Thus, both changes in the basal
insulin delivery rates and bolus administra-
tions did not affect the ability of the insulin
delivery catheter to predict plasma glucose
concentrations.
Insummary,herewehaveshownthat
glucose concentrations directly measured
at the subcutaneous insulin delivery site
canbeusedtoreliablyestimatebloodglu-
cose levels. Thus, glucose sensing and in-
sulin delivery may be simultaneously
performed at the same adipose tissue site
via a single tissue catheter. Such a single-
port treatment approach may provide the
basis for the development of an autono-
mous treatment device able to self-
regulate insulin delivery.
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